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Stopping targeted therapy 
for complete responders 
in advanced BRAF mutant 
melanoma
L. Warburton1,2, T. M. Meniawy1,3, L. Calapre2, M. Pereira2, A. McEvoy2, M. Ziman2,4, 
E. S. Gray 2* & M. Millward1,3
BRAF inhibitors revolutionised the management of melanoma patients and although resistance 
occurs, there is a subgroup of patients who maintain durable disease control. For those cases 
with durable complete response (CR) it is not clear whether it is safe to cease therapy. Here we 
identified 13 patients treated with BRAF +/− MEK inhibitors, who cease therapy after prolonged 
CR (median = 34 months, range 20–74). Recurrence was observed in 3/13 (23%) patients. In the 
remaining 10 patients with sustained CR off therapy, the median follow up after discontinuation was 
19 months (range 8–36). We retrospectively measured ctDNA levels using droplet digital PCR (ddPCR) 
in longitudinal plasma samples. CtDNA levels were undetectable in 11/13 cases after cessation 
and remained undetectable in patients in CR (10/13). CtDNA eventually became detectable in 2/3 
cases with disease recurrence, but remained undetectable in 1 patient with brain only progression. 
Our study suggests that consideration could be given to ceasing targeted therapy in the context of 
prolonged treatment, durable response and no evidence of residual disease as measured by ctDNA.
The identification of oncogenic mutations in BRAF led to the development of therapeutic options for patients 
with advanced  melanoma1. BRAF activating mutations, found in 40–50% of melanomas, result in activation of 
the Mitogen-activated protein kinases (MAPK) pathway. Highly specific mutant BRAF inhibitors have been 
approved for clinical use—vemurafenib, encorafenib and  dabrafenib2,3. These drugs have improved response 
rates, progression free survival (PFS) and overall survival (OS) in patients with stage IV BRAF mutant metastatic 
 melanoma4. The combination of BRAF inhibitors with MEK inhibitors has translated to the delayed evolution of 
resistance, resulting in improved progression free survival and outcomes for these  patients5–9. Four and five year 
OS has been shown to be around 30–40%, with PFS approximating 15%, demonstrating durable survival which 
appears to plateau at 4 years10,11. Patients with good prognostic features such as normal lactate dehydrogenase 
levels, low volume disease and good performance status had higher rates of durable control and  survival11–13. 
In the 5 year landmark analysis of COMBI-d, the patients who remained progression free at time of analysis, 
88% remained on combination BRAF and MEK  inhibition11. Targeted therapies for melanoma are relatively 
well tolerated with an excellent safety profile. It is unclear whether stopping targeted therapy in the setting of 
a complete response (CR) is a safe option. However, as healthcare costs continue to rise there is an increasing 
interest in the assessment of the cost–benefit of current regimes. Given the significant financial burden of these 
treatments, identifying patients that may be able to stop therapy in the absence of disease progression or toxicity 
should be evaluated.
Circulating tumour-derived cell free DNA (ctDNA) has been investigated as a potential biomarker of dis-
ease status in advanced melanoma patients. Short nucleic fragments, carrying genetic information including 
BRAF V600 mutations, are released by tumours allowing for blood based  monitoring14. Studies in colorectal 
cancer have shown the utility of ctDNA in measuring minimal residual disease as a predictor of recurrence and 
a way to stratify patients requiring additional  therapy15. Recent reports showed that ctDNA detection in plasma 
taken within 12 weeks of curative intent surgery is highly predictive of relapse in patients with stage II and III 
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 melanoma16,17. CtDNA responses in melanoma patients who have achieved a complete radiological response 
may be able to aid clinical decision making to determine if cessation of treatment is a viable option.
We present the outcomes of a case series of 13 patients who achieved complete tumour response following 
BRAF inhibitor monotherapy or combination BRAF/MEK inhibition, and ceased therapy for observation after 
maintaining sustained remission. This is a unique cohort as we have not included patients whom ceased due 
to toxicity. In addition, we analysed plasma samples from thirteen of these patients for the presence of BRAF 
mutant ctDNA as an indicator of disease presence.
Material and methods
Study design, setting and participants. We retrospectively reviewed the medical records of all 
patients with BRAF mutant metastatic melanoma who received first line BRAF inhibition monotherapy (vemu-
rafenib, encorafenib or dabrafenib) or combination BRAF/MEK therapy (dabrafenib and trametinib) treated 
at Sir Charles Gairdner Hospital, Perth, Western Australia from November 2009 to January 2019. We included 
only those patients that discontinued treatment after achieving a CR and had a minimum time on therapy of 
18 months. We excluded patients who stopped due to progressive disease or toxicity. The treatment was stopped 
after extensive discussion with the treating oncologist about the risks and benefits or at the request of the patient. 
The following information was collected: age, gender, Eastern Cooperative Oncology group (ECOG) perfor-
mance status, melanoma stage, number of metastatic sites, LDH at baseline, therapy instituted, duration of treat-
ment, time to CR, days off therapy and any toxicity reported. Recurrence was defined by disease recurrence at 
any site during observation according to standard RECIST criteria.
Blood collection. Plasma samples were collected from 13 patients analysed at various time points either 
during and/or prior to and beyond cessation of therapy or beyond cessation of therapy only. Samples were pro-
vided between April 2013 and May 2018. Written informed consent was obtained from all patients. The study 
was conducted according to the principles set out by the National Statement on Ethical Conduct in Human 
Research and Good Clinical Practice Guidelines by the National Health and Medical Research Council.
Blood collection and ctDNA analysis were perfomed as described previously in other publications from our 
 laboratory18–20. Patient peripheral blood samples were collected in EDTA and Streck tubes. Plasma was separated 
within 24 h by centrifugation at 300×g for 20 min, followed by a second centrifugation at 4700×g for 10 min, and 
then stored at – 80 °C until extraction. The cell free DNA (cfDNA) was extracted from 1 to 5 mL of plasma using 
the QIAamp Circulating Nucleic Acid Kit (Qiagen) as per the manufacturer’s instructions. Extracted samples 
were then frozen until analysis. The ctDNA was quantified by droplet digital PCR as previously  described18,19. 
Amplifications were carried out in a 20 μL reaction containing droplet PCR supermix, primers, probe and 
cfDNA. Samples were analysed for BRAF V600E or V600K mutations depending on the mutation identified in 
the patient’s biopsy. Droplets were generated and analysed using the QX200 system (Bio-Rad). Samples were 
analysed in triplicate, and considered positive if at least one triplicate was positive.
Ethical approval and consent to participate. The study was approved by the Human Research Ethics 
Committee of Edith Cowan University (No. 2932) and Sir Charles Gairdner Hospital (No. 2007-123).
Results
Patient characteristics and response to treatment. A total of thirteen patients that met the inclusion 
criteria were identified (Table 1). The median age was 61 years (38–71) and 54% were males. The baseline ECOG 
performance status was 0 in 11 patients. Two patients had baseline LDH greater than the upper limit of normal. 
There were three patients who had Stage M1a metastatic disease, one with M1b disease, five with M1c and four 
with M1d disease as per the AJCC TNM cancer staging system (8th edition). Three patients had more than three 
metastatic sites of disease. Four patients had brain metastasis at baseline; three of these patients had surgical 
excision with no radiological residual intracranial disease evident at commencement of therapy.
The patients all had confirmed BRAF V600E/K mutation in their melanoma on molecular analysis. Two 
patients had a V600K mutation and the rest were V600E mutant as tested by Sanger Sequencing on the original 
metastatic confirmatory biopsy. BRAF inhibition was the first line therapy in all 13 patients, with six patients 
treated with combination dabrafenib and trametinib, one patient received encorafenib, four received dabrafenib 
monotherapy and two received vemurafenib alone. Two patients required dose reductions for toxicity. They all 
achieved a CR to therapy. The mean time to CR was 9 months (median: 8, range 1–23).
The median observation period, from the commencement of therapy to census date was 57 months and 
19 months from cessation of BRAF inhibition (Fig. 1). The average duration of therapy was 39 months (median: 
34; range 20–73). The average time on therapy after a CR was achieved was 29 months (median: 24, range 11–73).
Melanoma recurrence. Recurrence, identified by PET/CT, was observed in three patients (Fig.  1). The 
median time to recurrence following treatment cessation was 5 months (range 5–11). All three patients had 
M1c/d melanoma with normal LDH and good performance status at baseline. Recurrence occurred in the 
encorafenib treated patient and in two dabrafenib and trametinib (CombiDT) treated patients. Two of these 
patients had recurrence in previous sites of disease, one patient had recurrence in a new site only. Two patients 
had recurrence in the brain.
ctDNA analysis. In total, we analysed 82 plasma samples from thirteen patients for the presence of ctDNA. 
One patient only provided one sample during treatment. As this was a retrospective analysis, the blood col-
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Table 1.  Patient cohort characteristics and outcome of patients treated with BRAF inhibition. AJCC American 
joint committee on cancer 8th edition, PD Progressive disease. *Patient 7 had a pre-existing diagnosis of 
ulcerative colitis which had remained quiescent prior to targeted therapy. Commencement of full dose 
combiDT flared diarrhoea and settled with dose reduction. Bold rows indicate patients that progressed after 
cessation of therapy.



















1 F 42 M1c V600K  < ULN  < 3 Lung, bones Dabrafenib – – No – – – –
2 M 70 M1c V600K  > 2 × ULN  > 3 Liver, lung, bones CombiDT – – No – – – –





Dabrafenib – – No – – – –
4 M 62 M1c V600E  < ULN  < 3 Liver, spleen CombiDT – – No – – – –




Vemurafenib – – No – – – –




Encorafenib Yes Skin Toxicity Yes 5 Brain CombiDT CR





Yes 5 Brain CombiDT PR




CombiDT – – Yes 11 Nodal CombiDT CR
9 M 66 M1b V600E  < ULN  < 3 Lung CombiDT – – No – – – –




Vemurafenib – – No – – – –
11 F 42 M1d V600E  > ULN  < 3 Brain, nodal Dabrafenib – – No – – – –
12 F 55 M1a V600E  < ULN  < 3 Nodal Dabrafenib – – No – – – –




CombiDT – – No – – – –
Figure 1.  Swimmers plot of all 13 patients treated with BRAF inhibitors. Time on treatment, time to complete 
response and time off treatment are indicated for each case. Arrows indicate continuation of complete response 
off therapy. Lines indicate plasma collection time points.
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lection time points were not consistent across the cohort. Only four cases had plasma collected at the time of 
therapy initiation, of those three were positive for ctDNA (Fig. 2). CtDNA levels became undetectable soon after 
treatment initiation in all three cases, remaining undetectable throughout therapy, at the time of cessation and 
after cessation.
CtDNA in 36 plasma samples collected during therapy from eight cases had undetectable ctDNA. In addi-
tion, we analysed 46 plasmas collected at or after cessation of therapy from 12 of the patients (Fig. 1). Except 
for three patients who relapsed (detailed below), all samples for patients at the time of treatment cessation and 
beyond had undetectable ctDNA.
In patient #6, melanoma recurred 5 months after cessation of encorafenib. He developed recurrence with a 
single solitary asymptomatic cerebellar metastasis detected on surveillance imaging. He did not previously have 
intracranial disease. This solitary metastasis was surgically resected and no additional disease was identified on 
staging scans. CtDNA was not detectable at time of initial recurrence. Unfortunately, samples were not available 
prior to initiation of therapy to determine if ctDNA was ever measurable at baseline. He was rechallenged with 
dabrafenib and trametinib achieving PFS of 7 months. He developed leptomeningeal involvement as confirmed 
by lumbar puncture and MRI brain. It is of note that the ctDNA level detectable in plasma at time of relapse 
was very low (1.6 copies/mL) but was very high in cerebrospinal fluid CSF (9500 copies/mL) (Figs. 2, 3). He 
was switched to combination immunotherapy, but unfortunately progressed with leptomeningeal disease with 
associated increasing plasma ctDNA levels (Fig. 2).
Patient #7 had intracranial and extracranial disease at baseline which responded to combination targeted 
therapy. Tumour recurrence was detected 5 months after cessation of dabrafenib and trametinib, and occurred 
intracranially at sites of original disease. No recurrence was observed in the original extracranial organ sites 
(liver, nodes). CtDNA levels were undetectable at the time of treatment cessation and on relapse. Dabrafenib and 
trametinib were restarted at full dose without toxicity. Early response assessment demonstrated a good partial 
response but progression was confirmed on imaging 4 months after rechallenge. She was switched to combina-
tion immunotherapy but unfortunately died of progressive intracranial melanoma eight months after relapse.
Patient #8 relapsed eleven months after stopping treatment. At relapse, tumour growth was observed in 
intraabdominal lymph nodes and was asymptomatic. Dabrafenib and trametinib was restarted and he attained 
partial response. Ongoing response was observed for 8.5 months after recommencement, with subsequent radio-
logical progression in intraabdominal nodes. CtDNA became detectable 3 months prior to radiological evidence 
of relapse (Fig. 2).
Figure 2.  Longitudinal tracking of ctDNA during and post treatment for patients 2, 4, 6 and 8. Time on 
therapy is highlighted in yellow for dabrafenib and trametinib, orange for encorafenib and pink for subsequent 
immunotherapy (ipilimumab and nivolumab). Disease assessments by radiological imaging are indicated by 
arrows and labelled as SD stable disease, PR partial response, CR complete response or PD progressive disease.
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Discussion
Here we present a case series of metastatic melanoma patients who stopped BRAF targeted therapy after obtain-
ing CR. Only three out of thirteen patients have relapsed with a median follow up period of 19 months since 
treatment was stopped. This is the longest published cessation and observation follow up study to date. Although 
this single centre retrospective study describes a small cohort of patients, it provides further insight into whether 
BRAF inhibitors can be safely discontinued in complete responders. In addition, it combines a unique perspec-
tive by incorporating clinical outcomes with circulating tumour DNA analysis and shows the efficacy of ctDNA 
as a measure of disease presence.
A 3 year analysis of patients on BRAF/MEK inhibition revealed 58% patients with CR had maintained CR 
at 3 years; of these, 21% had stopped treatment. No details are available about the median duration of time off 
 treatment21. Additionally, at 5 years, progression free survival rate (49%) and overall survival rate (70%) were 
significantly higher in patients with confirmed CR. At 5 years 23% of patients discontinued the study drug in 
the absence of disease  progression21.
Five other publications have described patient outcomes upon cessation of BRAF inhibitors (Table 2). Wyluda 
et al.22 described three cases of durable CR without relapse 15 months after treatment was ceased. These three 
patients were treated for a finite period with BRAF inhibitor after being initially unsuccessfully treated with 
immunotherapy. The other four publications described experiences with cessation of BRAF inhibitors in their 
patients. The majority of patients in these four series stopped due to toxicity (54–100%) with a relapse rate of 
between 46 and 53% after a median follow up of 12–17 months22–26.
Our cohort differs to those previously published as all 13 patients received BRAF inhibitors as first line 
treatment and cessation occurred after a lengthy period of treatment in CR, in the absence of treatment limit-
ing toxicity. Our median follow up since cessation is longer and relapse rate lower (Table 2). Vanhaecke et al.26 
described in their cohort that duration of treatment after CR was shorter in relapsing patients. Similarly, three 
patients in our cohort who relapsed were on treatment for a median of 16 months (range 12–23) after CR vs 
29.5 months (11–73) in the non-relapsing patients. Furthermore, the duration of treatment prior to cessation 
was significantly longer in our cohort compared to others described (median: 39 months) perhaps contributing 
Figure 3.  Cerebrospinal fluid-derived ctDNA. Level of ctDNA in CSF in patient #6, who developed 
leptomeningeal disease after re-challenge with targeted therapy. 2D plot from ddPCR analysis indicates the 
presence of DNA mutant for BRAF V600E (FAM, blue dots), BRAF wild-type (VIC, green dots) or both (orange 
dots). a.u. denotes the arbitrary unit for FAM and VIC probe intensity.






Number of patients 
(CR)
Median duration of 
BRAFi treatment 
(months)
Therapy ceased due 
to toxicity
Median follow up 
after treatment 
cessation (months) Relapse rate (%)






Wyluda et al.21 3 9–12 100% 15 0 N/A N/A
Tolk24 12 13 54% 17 46% 3 50%
Carlino22 12 N/A 100% 16 50% 6.6 33%
Vanhaecke25 16 21 63% 12 53% 2.5 63%
Desvignes23 6 10 100% 15 100% 4 17%
Warburton 13 39 0 19 23% 5 100%
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to the lower relapse rate  observed22–26. With respect to the 10 patients with ongoing response, it is difficult to 
appreciate any consistent pattern of clinical characteristics due to the small number. As reported in the literature, 
good prognostic indicators include good performance status, low number of metastatic sites, no CNS disease 
and normal  LDH10. However these clinical biomarkers are prognostic and not predictive and therefore within 
our small cohort, some patients with brain disease, high LDH and multiple metastatic sites continue to maintain 
CR despite cessation of therapy.
In the pooled 3-year analysis of clinical outcomes of patients treated with dabrafenib and trametinib 19% 
of patients achieved CR. Progression after CR occurred in 42%, 39% of whom were not on therapy at time of 
 progression12. Further analysis of the subgroup who progressed after CR (n = 106) by Robert et al. demonstrated 
that progression following CR was usually observed in new lesion organs (89%) and most commonly in CNS 
(54%)21. In our relapsing patients, 33% (n = 1) relapsed in a new organ location and 66% (n = 2) relapsed in the 
brain.
It has been reported that rechallenge with BRAF inhibitors in patients who initially respond is associated 
with further response and improvement in overall survival. In a series of 116 patients rechallenged with BRAF 
inhibitors objective response rates were 42% and PFS was 5 months (range 0.2–31.7) which was similar to our 
patients (median: 7 months, range 4–8.5)27. Additionally in Desvigne’s cohort of eleven patients, eight patients 
were rechallenged with a BRAF inhibitors with a median progression-free survival time of 7.2 months (range 
15–425 days)24. The first prospective clinical trial demonstrating objective response to dabrafenib and trametinib 
rechallenge hypothesized that the acquired mutation to BRAF inhibitors could be reversed when the selective 
pressure of BRAF inhibition was withheld. Patients (N = 25) who were off BRAF targeted therapy for at least 
12 weeks were rechallenged after progression. Partial response was achieved in 32% and stable disease in 40%28. 
Our cohort is different as the relapsed patients never experienced evidence of acquired resistance and progres-
sion during the primary course of targeted therapy. However, our results confirmed that patients who relapse 
post treatment can respond to reintroduction of BRAF/MEK inhibitors.
CtDNA is emerging as a promising blood biomarker to indicate initial tumour burden, monitor treatment 
response, evaluate dynamic mutational changes and predict for minimal residual disease in melanoma and 
other  cancers18,29,30. In melanoma, several studies have shown the clinical utility of using ctDNA for tracking 
response to therapy and  prognostication18,20,29–34. Baseline ctDNA levels have been shown to be directly associated 
with radiological tumour burden and inversely associated with response and  PFS34–37. Low levels of ctDNA are 
associated with better responses to targeted therapy and reductions in ctDNA levels an independent predictor 
of response to BRAF inhibitor  therapy18. Furthermore, Lee et al.30 and Cabel et al.38 have both shown that unde-
tectable ctDNA at baseline or within eight weeks of commencing anti PD1 therapy is an independent predictor 
of response and PFS. There have been no studies to date that investigate ctDNA as an indicator or predictor for 
safe early cessation of therapy and durable PFS.
Lee et al.39 published compelling data demonstrating that ctDNA can detect minimal residual disease which 
also corresponded to poorer outcome and survival in patients with high risk stage II and III resected melanoma. 
Similarly, in breast and colon cancer, as well as more recent melanoma studies have again shown that detectable 
ctDNA after curative resection is associated with recurrence and worse  survival15–17,40. Analysis of ctDNA in 
patients who are stopping BRAF-inhibitors may reveal which patients have minimal residual disease and would 
benefit from ongoing targeted treatment. All 13 patients who contributed blood samples had undetectable ctDNA 
either during, at completion or after cessation of therapy. Unfortunately it appears that a limitation of ctDNA is 
in its detection of intracranial disease, likely accounting for the unmeasurable levels in both patients #6 and #7 
who recurred  intracranially41–43.
There appears to be a subgroup of patients, as demonstrated in our and previously published series, that attain 
CR and maintain it after treatment is stopped. Our retrospective study has a number of inherent limitations 
including the small sample size, the inconsistent blood collection time points across the patients and the absence 
of blood collection and analysis prior to commencement of treatment for eight of the patients. Clearly with no 
prospective data available to guide treatment cessation decisions, stopping BRAF inhibitors in CR cannot be 
widely recommended. Our study gives credence to the fact that further studies about treatment cessation are 
required in patients who have good prognostic clinical features, have tolerated a prolonged treatment course 
with CR (> 2 years) and have undetectable ctDNA. Currently there are no clinical or biomarker correlates that 
assist clinicians in counselling patients to cease or continue treatment. Our study shows promise that ctDNA 
may aid these decisions. However, ctDNA has inherent limitations in patients with low volume disease and 
brain metastases where it can remain undetectable despite relapse. Larger, prospective studies are needed to 
select appropriate patients and optimise the timing of treatment discontinuation, and the incorporation of novel 
surrogate endpoints such as ctDNA in clinical decision-making, with the ultimate aim to mitigate unnecessary 
toxicity and treatment expense.
Data availability
All data generated or analyzed during this study are included in this published article and its supplementary 
information files.
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